Department of Pediatrics, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
PLoS One. 2022 Feb 23;17(2):e0263215. doi: 10.1371/journal.pone.0263215. eCollection 2022.
Whether high D-dimer level before treatment has any impact on poor outcomes in patients with community-associated pneumonia (CAP) remains unclear. Therefore, we conducted the first meta-analysis focusing specifically on prognostic value of high D-dimer level before treatment in CAP patients.
Pubmed, Embase, the Cochrane Central Register of Controlled Trials and World Health Organization clinical trials registry center were searched up to the end of March 2021. Randomized clinical trials (RCT) and observational studies were included to demonstrate the association between the level of D-dimer and clinical outcomes. Data were extracted using an adaptation of the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF). When feasible, meta-analysis using random-effects models was performed. Risk of bias and level of evidence were assessed with the Quality in Prognosis Studies tool and an adaptation of Grading of Recommendations Assessment, Development, and Evaluation. Data were analyzed using STATA 14.0 to complete meta and network analysis.
Besides d-dimer levels in CAP patients with poor outcomes, we also analyzed proportion of patients with or without poor outcomes correctly classified by the d-dimer levels as being at high or low risk. The poor outcome includes severe CAP, death, pulmonary embolism (PE) and invasive mechanical ventilators.
32 studies with a total of 9,593 patients were eventually included. Pooled effect size (ES) suggested that d-dimer level was significantly higher in severe CAP patients than non-severe CAP patients with great heterogeneity (SMD = 1.21 95%CI 0.87-1.56, I2 = 86.8% p = 0.000). D-dimer level was significantly elevated in non-survivors compared to survivors with CAP (SMD = 1.22 95%CI 0.67-1.77, I2 = 85.1% p = 0.000). Prognostic value of d-dimer for pulmonary embolism (PE) was proved by hierarchical summary receiver operating characteristic curve (HSROC) with good summary sensitivity (0.74, 95%CI, 0.50-0.89) and summary specificity (0.82, 95%CI, 0.41-0.97). Network meta-analysis suggested that there was a significant elevation of d-dimer levels in CAP patients with poor outcome than general CAP patients but d-dimer levels weren't significantly different among poor outcomes.
The prognostic ability of d-dimer among patients with CAP appeared to be good at correctly identifying high-risk populations of poor outcomes, suggesting potential for clinical utility in patients with CAP.
治疗前高 D-二聚体水平是否对社区获得性肺炎(CAP)患者的不良结局有影响尚不清楚。因此,我们进行了首次荟萃分析,专门关注治疗前高 D-二聚体水平对 CAP 患者的预后价值。
检索 Pubmed、Embase、Cochrane 中央对照试验注册中心和世界卫生组织临床试验注册中心,截至 2021 年 3 月底。纳入随机临床试验(RCT)和观察性研究,以证明 D-二聚体水平与临床结局之间的关系。使用预测模型研究的关键评估和数据提取清单(CHARMS-PF)的改编版提取数据。在可行的情况下,使用随机效应模型进行荟萃分析。使用预后研究质量工具和推荐评估、制定和评估的改编版评估风险偏倚和证据水平。使用 STATA 14.0 分析数据以完成荟萃分析和网络分析。
除了 CAP 患者不良结局的 D-二聚体水平外,我们还分析了 D-二聚体水平正确分类为高风险或低风险的 CAP 患者中存在或不存在不良结局的比例。不良结局包括严重 CAP、死亡、肺栓塞(PE)和有创机械通气。
最终纳入了 32 项研究,共 9593 名患者。汇总效应量(ES)表明,严重 CAP 患者的 D-二聚体水平明显高于非严重 CAP 患者,且异质性很大(SMD=1.21,95%CI 0.87-1.56,I2=86.8%,p=0.000)。与 CAP 幸存者相比,非幸存者的 D-二聚体水平明显升高(SMD=1.22,95%CI 0.67-1.77,I2=85.1%,p=0.000)。分层综合接收者操作特征曲线(HSROC)证明了 D-二聚体对肺栓塞(PE)的预后价值,具有良好的综合敏感性(0.74,95%CI,0.50-0.89)和综合特异性(0.82,95%CI,0.41-0.97)。网络荟萃分析表明,不良结局的 CAP 患者的 D-二聚体水平明显升高,但不良结局的 D-二聚体水平之间没有显著差异。
D-二聚体在 CAP 患者中的预后能力似乎能够很好地识别不良结局的高危人群,提示其在 CAP 患者中具有潜在的临床应用价值。